Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.90
-2.0%
$12.34
$10.45
$21.69
$4.92B0.62720,946 shs294,386 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$97.76
-1.3%
$98.13
$77.10
$163.71
$5.59B0.82748,221 shs599,069 shs
Inari Medical, Inc. stock logo
NARI
Inari Medical
$79.97
$79.97
$39.76
$79.99
$4.68B1.021.47 million shsN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$1.09
-5.2%
$1.13
$0.59
$4.49
$18.73M3.7571,180 shs140,619 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+1.63%-0.05%+22.58%+17.54%-15.43%
Glaukos Corporation stock logo
GKOS
Glaukos
+0.48%-7.18%-1.03%+9.80%-20.26%
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.00%0.00%0.00%0.00%+36.42%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
+13.86%+15.46%+2.68%-31.89%-14.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.7027 of 5 stars
2.12.00.00.00.61.72.5
Glaukos Corporation stock logo
GKOS
Glaukos
4.3756 of 5 stars
4.41.00.04.42.71.70.6
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.2677 of 5 stars
1.10.00.00.00.02.50.6
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
3.0343 of 5 stars
3.55.00.00.02.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.17
Hold$15.4511.18% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6737.75% Upside
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.14
Hold$69.22-13.44% Downside
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
3.00
Buy$5.00358.72% Upside

Current Analyst Ratings Breakdown

Latest NXL, GKOS, BLCO, and NARI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Glaukos Corporation stock logo
GKOS
Glaukos
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$13.00 ➝ $15.00
7/8/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.50 ➝ $16.00
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
5/6/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
5/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $12.00
5/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $15.50
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.03$1.86 per share7.46$18.57 per share0.75
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M14.57N/AN/A$13.91 per share7.03
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M9.48$0.09 per share906.95$8.07 per share9.91
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$170K110.15N/AN/A$0.28 per share3.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.481.57-7.50%2.62%1.28%7/30/2025 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$7.61M-$0.83N/AN/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)

Latest NXL, GKOS, BLCO, and NARI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
5/13/2025Q1 2025
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
1.77
1.40
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/A
4.56
4.25

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
0.65%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
25.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.80 million351.12 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.83 millionOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
80058.54 million52.34 millionOptionable
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
317.18 million12.84 millionNot Optionable

Recent News About These Companies

Nexalin Technology receives IRB approval in Brazil, begins trial
Nexalin completes five phases of virtual clinic, digital research system

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.90 -0.28 (-1.97%)
Closing price 03:59 PM Eastern
Extended Trading
$13.91 +0.01 (+0.07%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$97.76 -1.24 (-1.25%)
Closing price 03:59 PM Eastern
Extended Trading
$97.72 -0.04 (-0.04%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Inari Medical stock logo

Inari Medical NASDAQ:NARI

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Nexalin Technology stock logo

Nexalin Technology NASDAQ:NXL

$1.09 -0.06 (-5.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.10 +0.01 (+0.92%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.